Myeloid checkpoint blockade improves killing of T-acute lymphoblastic leukemia cells by an IgA2 variant of daratumumab.

Antibody-based immunotherapy is increasingly employed to treat acute lymphoblastic leukemia (ALL) patients. Many T-ALL cells express CD38 on their surface, which can be targeted by the CD38 antibody daratumumab (DARA), approved for the treatment of multiple myeloma. Tumor cell killing by myeloid cells is relevant for the efficacy of many therapeutic antibodies and can be more efficacious with human IgA than with IgG antibodies.

An evidence-based determination of issues affecting quality of life and patient-reported outcomes in lung cancer: results of a survey of 660 patients.

Introduction: Identifying issues of importance for patients with lung cancer is critical in individualizing care and developing effective quality of life instruments based on evidence. This study was conducted to provide enhanced content validity for measures assessing quality of life and patient-reported outcomes (PROs).

Methods: We conducted an anonymous, cross-sectional, electronic web-based survey of 660 lung cancer patients.

Patient income level and cancer clinical trial participation.

Purpose: Studies have shown an association between socioeconomic status (SES) and quality of oncology care, but less is known about the impact of patient SES on clinical trial participation.

Patients And Methods: We assessed clinical trial participation patterns according to important SES (income, education) and demographic factors in a large sample of patients surveyed via an Internet-based treatment decision tool. Logistic regression, conditioning on type of cancer, was used.

Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials.

There is limited information available regarding the reasons cancer patients decide to enter clinical trials. To explore this issue, aggregate responses to the question, "Are you interested in learning about clinical trials for your condition?" obtained from >115,000 cancer patients (or their families) who entered data into 1 of several proprietary decision-support programs embedded within approximately 100 well-established cancer-related Internet sites were analyzed. The percentage of patients (or their families) who expressed interest in learning about clinical trials ranged from as low as 21% (endometrial and cervix cancer patients >80 years of age; n=178) to as high as 85% (recurrent ovarian cancer patients, age 51-60; n=842).

Profile of ovarian cancer patients seeking information from a web-based decision support program.

Background: There is limited information available regarding the characteristics of patients who elect to gather and share information about their malignancy on the Internet.

Methods: Using a proprietary decision support program embedded into a number of established websites, individuals entered personal clinical data into disease site profilers designed to provide information about evidence-based treatment options, based on specific characteristics (e.g.

Clinical features of American versus non-American gynecologic cancer patients requesting information from a proprietary web-based decision-support program.

Purpose: As the Internet can potentially substantially reduce geographic barriers to the dissemination of health-related information, it would be interesting to know if non-American women with gynecologic malignancies accessing United States (US)-based cancer Web sites differ from American patients with the same illness.

Patients And Methods: Aggregate data from individuals providing personal clinical information into one of four proprietary gynecologic cancer (cervix, endometrial, newly diagnosed and recurrent ovarian cancers) decision-support programs (NexProfiler Treatment Option Tools for Cancer; NexCura Inc., Seattle WA, USA) currently embedded within approximately 100 established cancer-related Web sites were examined for differences between American versus non-American patient populations.

An examination of characteristics of lung and colon cancer patients participating in a web-based decision support program. Internet-based decision support programs.

Objectives: Little is known about the characteristics of cancer patients who employ the Internet as a technique to gather information to assist them in their management.

Methods: To address this issue, aggregate data from individuals with colon (n=7,543), non-small cell lung (n=24,778) and small cell lung (n=13,817) cancers who provided personal clinical information through participation in a proprietary Web-based decision support program (NexProfiler Treatment Option Tools for Cancer; NexCura, Inc., Seattle, Wash.